Form 4: Karyopharm Therapeutics EVP Sohanya Cheng Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
EVP & Chief Commercial Officer of Karyopharm Therapeutics, Sohanya Cheng, sold shares of common stock to cover withholding tax liabilities related to vesting restricted stock units.
Summary
- Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics, reported the sale of company shares.
- The sales were executed on February 29, 2024, and March 1, 2024.
- These transactions were conducted under a pre-arranged automatic sale plan adopted on June 7, 2022, to cover withholding tax obligations.
- On February 29, 2024, 21,840 shares were sold at an average price of $1.17.
- On March 1, 2024, 5,109 shares were sold at $1.2.
- Following these transactions, Cheng directly owns 393,509 shares of Karyopharm Therapeutics.
- The sales were not discretionary trades but were part of a plan to manage tax liabilities from vested stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing relates to routine stock sales for tax purposes under a pre-arranged plan, not indicative of management's view on the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but the pre-arranged nature of the sales mitigates concerns about insider trading or lack of confidence in the company.
Key Dates
| Date | Description |
|---|---|
| June 7, 2022 | Date of adoption of the durable automatic sale instruction plan. |
| February 29, 2024 | Date of the first reported transaction: sale of 21,840 shares. |
| March 1, 2024 | Date of the second reported transaction: sale of 5,109 shares. |
| March 4, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.